Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting
March 15 2023 - 11:00AM
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a
clinical-stage biopharmaceutical company using protein inhibition
and protein degradation to develop cancer therapies for patients in
need of new treatment options, today announced that two abstracts
related to the company’s novel molecular glue SP-3164 have been
accepted for presentation at the American Association for Cancer
Research (AACR) Annual Meeting, being held April 14-19 at the
Orange County Convention Center in Orlando, Florida and also
virtually. Both abstracts highlight preclinical activity with
SP-3164, one focused on non-Hodgkin’s lymphoma (NHL) and the other
on multiple myeloma (MM).
One abstract is titled “SP-3164, a novel Ikaros
and Aiolos molecular glue degrader with preclinical activity in
non-Hodgkin lymphomas,” and concludes that SP-3164 is a novel,
orally available, cereblon-binding molecular glue with attractive
therapeutic properties and significant anticancer activity in NHL
cell line and animal models. Further assessment of SP-3164’s
potential as a treatment for NHLs is warranted and a clinical trial
is planned to start in 2023.
The other abstract, titled “SP-3164, a novel
molecular glue degrader with activity in preclinical models of
multiple myeloma,” concludes that SP-3164 is a potent
cereblon-binding molecular glue with the ability to rapidly degrade
cancer-promoting proteins and induce cell death in multiple myeloma
cell lines. In multiple myeloma animal models, SP-3164 has superior
single agent and combination treatment activity compared to
approved molecular glues. These data support the continued
development of SP-3164 as a novel therapy in MM.
The abstracts were published yesterday afternoon
and are now available on the AACR website at https://www.aacr.org.
Details of the presentations are as follows:
SP-3164 NHL Presentation |
Title: “SP-3164, a novel Ikaros and Aiolos molecular glue degrader
with preclinical activity in non-Hodgkin lymphomas” |
Session Category: Experimental and Molecular Therapeutics |
Session Title: Novel Antitumor Agents 2 |
Session Date and Time: Sunday Apr. 16, 2023, 1:30 PM - 5:00 PM |
Location: Poster Section 18 |
Poster Board Number: 24 |
Published Abstract Number: 524 |
Presenter: Daniela Santiesteban, Ph.D., Director of Targeted
Protein Degradation Development, Salarius |
|
SP-3164 MM Presentation |
Title: “SP-3164, a novel molecular glue degrader with activity in
preclinical models of multiple myeloma” |
Session Category: Experimental and Molecular Therapeutics |
Session Title: DNA-reactive Agents, HDAC and Methyltransferase
Inhibitors, and Tubulin Agents |
Session Date and Time: Wednesday Apr. 19, 2023, 9:00 AM - 12:30
PM |
Location: Poster Section 19 |
Poster Board Number: 23 |
Published Abstract Number: 6253 |
Presenter: Aundrietta D. Duncan, Ph.D., Director, Non-Clinical
Development, Salarius |
Following the presentations at AACR, both
posters will be available on Salarius’ website at
www.salariuspharma.com.
About Salarius
PharmaceuticalsSalarius Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company developing therapies for
patients with cancer in need of new treatment options. Salarius’
product portfolio includes seclidemstat, Salarius’ lead candidate,
which is being studied as a potential treatment for pediatric
cancers, sarcomas and other cancers with limited treatment options,
and SP-3164, an oral small molecule protein degrader. Seclidemstat
is currently in a Phase 1/2 clinical trial for relapsed/refractory
Ewing sarcoma and certain additional sarcomas that share a similar
biology. This trial is currently on a partial clinical hold and is
not enrolling new patients. Seclidemstat has received fast track,
orphan drug and rare pediatric disease designations for Ewing
sarcoma from the U.S. Food and Drug Administration. Salarius is
also exploring seclidemstat’s potential in several cancers with
high unmet medical need, with an investigator-initiated Phase 1/2
clinical study in hematologic cancers at MD Anderson Cancer Center.
This trial is also currently on a partial clinical hold and is not
enrolling new patients. Salarius has received financial support
from the National Pediatric Cancer Foundation to advance the Ewing
program and was a recipient of a Product Development Award from the
Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164
is currently in IND-enabling studies and anticipated to enter the
clinic in 2023. For more information, please visit
salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Forward-Looking Statements This
announcement and the referenced presentations contain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, included in this announcement
and the referenced presentations are forward-looking statements.
These forward-looking statements may be identified by terms such as
“will,” “future,” “believe,” “developing,” “expect,” “may,”
“progress,” “potential,” “could,” “look forward,” “might,”
“should,” and similar terms or expressions or the negative thereof.
Examples of such statements include, but are not limited to,
statements relating to the following: the advantages of
seclidemstat (SP-2577) as a treatment for Ewing sarcoma,
Ewing-related sarcomas, and other cancers and its ability to
improve the life of patients; expected cohort readouts from the
company’s clinical trials and expected therapeutic options for
SP-2577 and related effects and projected efficacy, including
SP-2577’s ability to inhibit LSD1; the future of the company’s
Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma
and FET-rearranged sarcomas following the recently announced
suspected unexpected severe adverse reaction (SUSAR) event and
resulting partial clinical hold by the U.S. Food and Drug
Administration (FDA); the advantages of protein degraders including
the value of SP-3164 as a cancer treatment; the timing of clinical
trials for SP-3164 and expected therapeutic options for SP-3164 and
related effects and projected efficacy; impact that the addition of
new clinical sites will have on the development of our product
candidates; the timing of our IND submissions to the FDA and
subsequent timing for initiating clinical trials; interim data
related to our clinical trials, including the timing of when such
data is available and made public; our growth strategy; whether the
company will develop additional undisclosed cancer-fighting
assets in the targeted protein degradation space; expanding the
scope of our research and focus to high unmet need patient
populations; and the commercial or market opportunity and expansion
for each therapeutic option, including the availability and value
of a pediatric priority review voucher for in-clinic treatments and
potential for accelerated approval. We may not actually achieve the
plans, carry out the intentions or meet the expectations or
objectives disclosed in the forward-looking statements. You should
not place undue reliance on these forward-looking statements. These
statements are subject to risks and uncertainties which could cause
actual results and performance to differ materially from those
discussed in the forward-looking statements. These risks and
uncertainties include, but are not limited to, the following:
Seclidemstat’s impact in Ewing sarcoma and as a potential new and
less-toxic treatment; expected dose escalation and dose expansion;
resolution of the FDA’s partial clinical hold on the company’s
Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma
and FET-rearranged sarcomas following the SUSAR; our ability to
resume enrollment in the clinical trial following its review of the
available data surrounding the SUSAR; the adequacy of our capital
to support our future operations and our ability to successfully
initiate and complete clinical trials and regulatory submissions;
the ability of, and need for, us to raise additional capital to
meet our business operational needs and to achieve its business
objectives and strategy; future clinical trial results and the
impact of such results on us; that the results of studies and
clinical trials may not be predictive of future clinical trial
results; risks related to the drug development and the regulatory
approval process; the competitive landscape and other
industry-related risks; and other risks described in our filings
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2021, as
revised or supplemented by its Quarterly Reports on Form 10-Q and
other documents filed with the SEC. The forward-looking statements
contained in this announcement and the referenced presentations
speak only as of the date of this announcement and the referenced
presentations and are based on management’s assumptions and
estimates as of such date. We disclaim any intent or obligation to
update these forward-looking statements to reflect events or
circumstances that exist after the date on which they were
made.
CONTACT:
LHA Investor RelationsKim Sutton Golodetz
kgolodetz@lhai.com212-838-3777
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Jul 2023 to Jul 2024